The Oncologist-Patient Partnership

Lorbrena demonstrated longer progression-free survival and improved time to intracranial progression, compared with Xalkori in ALK-positive non-small cell lung cancer.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

Onivyde did not outperform chemotherapy in improving outcomes for patients with relapsed small cell lung cancer, despite having better response rates.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

When it comes to high blood sugar, cancer and diabetes can create a “vicious cycle,” as one expert explained.

The Food and Drug Administration approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung cancer that progressed on or after a platinum-based chemotherapy.